The First Life Saved by CRISPR Base Editing
Alyssa was 13 when her doctors ran out of options. Three rounds of chemotherapy had failed.
A bone marrow transplant had failed. Her parents were looking at remortgaging their house to seek experimental treatment abroad. Then a team at Great Ormond Street Hospital in London offered her something nobody had ever tried: T-cells edited with CRISPR base editing to target leukemia without destroying themselves. The catch is that T-cell leukemia is usually untreatable with CAR-T therapy, because modified T-cells attack each other. CRISPR base editing changed that. The team altered specific DNA letters in donor T-cells so they could hunt leukemia without triggering self-destruction. The treatment worked. Alyssa is alive. She is the first person on earth whose life was saved by CRISPR base editing [16]. In the same week, a paper in Nature reported that a similar approach, using three different delivery platforms to train the immune system against HIV-1, achieved neutralization breadth against 90% of diverse viral strains in macaques within 12 weeks, with broadly neutralizing antibodies appearing as early as 4 weeks [7].
What each field noticed (2)
I'm the first person whose life was saved by CRISPR base editing
Alyssa's own words are what make this account impossible to skim. She was 13, in a hospital, thinking she would never grow up. "I was thinking: Oh my gosh, this is my last birthday." The trial at Great Ormond Street involved a kind of genetic engineering that was new: not cutting DNA but chemically rewriting single letters of it, with more precision and fewer off-target effects than earlier CRISPR methods. When the team described what would happen, it sounded like science fiction. "They were like: we're gonna put some CAR Ts in, and they're gonna multiply and multiply some more, and go around and fight and kill all your cancer cells." They did [16].
Read the storyEnhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies
Nature's paper this week described a different disease and a different approach but the same underlying ambition: use what we now know about genetics to teach the immune system to recognize things it has historically failed to recognize. The HIV-1 vaccine work used protein nanoparticles and mRNA alongside viral delivery to prime macaques' immune systems to produce broadly neutralizing antibodies, the kind that can stop diverse strains of a highly variable virus. In 14 infected macaques, neutralization breadth reached as high as 90% on a 21-virus panel. The team described it as "a molecular blueprint" for inducing these antibodies in humans [7].
Read the story





